Compare MERC & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MERC | ACOG |
|---|---|---|
| Founded | 1968 | 2000 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Paper | |
| Sector | Basic Materials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 115.5M |
| IPO Year | 1987 | N/A |
| Metric | MERC | ACOG |
|---|---|---|
| Price | $2.07 | $5.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $3.00 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 737.4K | 104.1K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 7.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,906,971,000.00 | $7,427,199.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.53 | $132.35 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.48 | $3.75 |
| 52 Week High | $8.28 | $11.54 |
| Indicator | MERC | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 55.95 |
| Support Level | $1.98 | $5.61 |
| Resistance Level | $2.15 | $6.20 |
| Average True Range (ATR) | 0.12 | 0.57 |
| MACD | 0.03 | 0.10 |
| Stochastic Oscillator | 51.82 | 74.00 |
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.